Author

J. F. Diaz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1 Approach:statistical model· 1 Assay:structural biology· 1

Frequent Co-Authors

A. E. Prota· 1 shared D. Lucena-Agell· 1 shared D. Sackett· 1 shared E. V. Navarro· 1 shared F. Josa-Prado· 1 shared G. Galletti· 1 shared H. V. Goodson· 1 shared I. Barasoain· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiophysics

A. E. Prota

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Structural insight into the stabilization of microtubules by taxanes

A. E. Prota, D. Lucena-Agell, Y. Ma, J. Estevez-Gallego, S. Li, K. Bargsten, F. Josa-Prado, J. M. Andreu, K.-H. Altmann, N. Gaillard, S. Kamimura, T. Muehlethaler, M. A. Oliva, M. O. Steinmetz, W.-S. Fang, J. F. Diaz

This study determines the crystal structures of taxane-tubulin complexes and uses simulations to elucidate how taxanes stabilize microtubules through conformational changes and ligand binding.

bioRxiv · Jul 20, 2021Biophysics

Imatinib overrides taxane resistance by selective inhibition of novel CLIP1 variant obstructing the microtubule pore

K. Kita, P. V. Thakkar, G. Galletti, N. Madhukar, E. V. Navarro, I. Barasoain, H. V. Goodson, D. Sackett, J. F. Diaz, O. Elemento, M. A. Shah, P. Giannakakou

The paper identifies a novel CLIP-170 variant, CLIP-170S, that causes taxane resistance in gastric cancer and shows imatinib can reverse this resistance by selectively inhibiting CLIP-170S.

bioRxiv · Nov 11, 2019 · PreprintCancer Biology